Bristol-myers Squibb Compnay

Bristol-myers Company

Bristol Meyers Squibb Company

Daniel R Schroeder

Kin S Lam

Jacqueline M Mattei

Grace A Hesler

Koji Tomita

Jacqueline M Veitch

James A Matson

Salvatore Forenza

Donald R Gustavson

Ronald L Berry

Sandra J Hofstead

Thomas T Dabrah

Kin Sing Lam

James Andrew Matson

Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.

Rebeccamycin analogs by tryptophan analogs feeding

A certain fermentation product of Actinomadura strain Q473-8 yield, when suitably treated, a novel compound having both antibiotic and antitumor activities.

Antitumor antibiotic

A certain fermentation product of Actinomadura strain Q473-8 yields, when suitably treated, a novel compound having both antibiotic and antitumor activities.

Antitumor process employing novel fermentate of an Actinomadura strain

An antibiotic designated BMY-42448 is produced by fermentation of Micromonospora narashinoensis strain C39217-R109-7 (ATCC-53791). BMY-42448 exhibits both in vitro and in vivo antitumor activity.

Antitumor antibiotic BMY-42448

Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.

Rebeccamycin

An antitumor antibiotic designated BMY-42428 is produced by fermentation of Actinomadura madurae ATCC-53806. The BMY-42428 antibiotic exhibits both antimicrobial and antitumor activities.

Antitumor antibiotic BMY-42428

A new antibiotic designated BMY-42448 is produced by fermentation of Micromonospora narashinoensis strain C39217-R109-7 (ATCC-53791). BMY-42448 exhibits both in vitro and in vivo antitumor activity.

An antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.

BMY-41950 antitumor antibiotic

A new antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.

A fermentation process for preparing staurosporine, a known antibiotic, employing a heretofore unknown micrrorganism is described, said microorganism being classified as a novel strain of Streptomyces hygroscopicus being and herein designated Streptomyces hygroscopicus strain C39280-450-9 (ATCC 53730).

Growing community of inventors

Higganum, CT, United States of America

Daniel R Schroeder